Quantum BioPharma begins trading on Upstream a

TORONTO - Quantum (NASDAQ:QMCO) BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91)(Upstream:QNTM), a biopharmaceutical company, has announced its dual listing on Upstream, a global securities trading app operated by MERJ Exchange market. Starting today, international investors can access Quantum shares on the app, expanding the company's reach beyond its current listings on the Nasdaq, Canadian Securities Exchange, and Frankfurt exchanges. The company's shares, currently trading at $3.38, have seen significant volatility, trading between $2.70 and $70.85 over the past 52 weeks, according to InvestingPro data.

The dual listing is designed to streamline the process for global investors to engage with Quantum's shares using the Upstream app. However, U.S. persons are restricted from depositing, buying, or selling securities on Upstream. The Upstream market operates 20 hours a day, seven days a week, offering real-time trading and settlement with a transparent orderbook.

Quantum BioPharma is focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates at various stages of development. The company, through its subsidiary Lucid (NASDAQ:LCID) Psycheceuticals Inc., is advancing research on a compound intended to prevent and reverse myelin degradation in multiple sclerosis. While currently unprofitable, InvestingPro analysis suggests the company is undervalued, with strong liquidity indicators showing current assets exceeding short-term obligations by 3.76x. InvestingPro subscribers have access to 12 additional key insights about Quantum's financial health and market position.

Zeeshan Saeed, CEO of Quantum, expressed enthusiasm about the dual listing, citing the opportunity to add value and liquidity for shareholders while reaching a modern, global investor base.

The company also has strategic investments through FSD Strategic Investments Inc., and retains a 25.71% stake in Celly Nutrition Corp., which is responsible for the OTC version of Quantum's UNBUZZD™ product. The arrangement with Celly Nutrition includes a royalty payment structure based on sales.

Investors interested in Quantum's shares on Upstream can download the app, complete a KYC identity verification, and either deposit their Quantum shares or fund their account to purchase shares. For comprehensive financial analysis and real-time insights, investors can access detailed metrics and valuations through InvestingPro, including exclusive Fair Value calculations and financial health scores.

The information in this article is based on a press release statement from Quantum BioPharma Ltd. and is intended for informational purposes only.

In other recent news, Quantum BioPharma Ltd. has made significant progress with its clinical trial for the drug candidate Lucid-21-302, as the safety review committee recommends moving to the second cohort dosing phase. The company has also announced a non-brokered private placement of convertible debenture units to raise capital for business development and general working capital. Furthermore, Quantum BioPharma has initiated legal action against CIBC (TSX:CM) World Markets and RBC Dominion Securities for alleged market manipulation.

The company continues to advance its drug candidates, notably Lucid-21-302 for the treatment of multiple sclerosis, through its subsidiary Lucid Psycheceuticals Inc. Quantum BioPharma also holds a 25.71% ownership stake in Celly Nutrition Corp. and receives royalty payments from sales of the OTC product UNBUZZD™.

In a significant development, Quantum BioPharma has announced plans to dual list its shares on Upstream, a MERJ Exchange market, aiming to broaden its global investor base. These are recent developments in the biopharmaceutical sector. Quantum BioPharma's licensee, Celly Nutrition Corp., has secured a master distribution agreement with FUSION Consulting Group to distribute its alcohol metabolism supplement, unbuzzd™, across Puerto Rico, the Caribbean, and parts of Central and South America.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.